The company was founded in 1992 and is a national high-tech enterprise and a national innovative pilot enterprise engaged in R&D, production and sales of biological products such as blood products, vaccines, recombinant proteins, etc. The blood products sector has many blood products under the “Hualan” brand, such as human blood albumin, intravenous human immunoglobulin, human immunoglobulin, human prothrombin complex, and surgical freeze-dried human fibrin gel. It is one of the enterprises in China's blood products industry with a high comprehensive utilization rate of plasma, many varieties, and complete specifications. The company is a national high-tech enterprise engaged in R&D, production and sales of blood products, vaccines and genetic engineering products. The company's business includes three types of business: research and development and production of blood products, vaccine products, innovative drugs and biosimilar drugs. The company's main products: human blood albumin, intravenous human immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, rabies patient immunoglobulin, tetanus human immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human fibrin gel, topical freeze-dried human thrombin, influenza virus lytic vaccine, influenza virus lysis vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hanson vaccine) yeast), group A group C meningococcal polysaccharide vaccine, quadrivalent influenza virus lysis vaccine, freeze-dried for human use Rabies vaccine (Vero cell), adsorbed tetanus vaccine. Corporate honors: National certified enterprise technology center title, national key new product certificate, Ukrainian GMP certification, etc.